Have a personal or library account? Click to login
The pathophysiology and prevention of transfusion-related acute lung injury (TRALI): a review Cover

The pathophysiology and prevention of transfusion-related acute lung injury (TRALI): a review

By:
Paid access
|Mar 2020

References

  1. Stainsby D, Jones H, Asher D, et al. Serious hazards of transfusion: a decade of hemovigilance in the UK. Transfus Med Rev 2006;20:273–82.10.1016/j.tmrv.2006.05.00217008165
  2. Wendel S, Biagini S, Trigo F, et al. Measures to prevent TRALI. Vox Sang 2007;92:258–77.10.1111/j.1423-0410.2006.00870.x17348877
  3. U.S. Food and Drug Administration. Fatalities reported to FDA following blood collection and transfusion: annual summary for fiscal year 2009. Rockville, MD: U.S. Department of Health and Human Services, 2009. Available from: http://www. fda.gov/BiologicsBloodVaccines/SafetyAvailability/ReportaProblem/TransfusionDonationFatalities/ucm204763.htm.
  4. Boshkov LK. Transfusion-related acute lung injury and the ICU. Crit Care Clin 2005;21:479–95.10.1016/j.ccc.2005.05.00515992669
  5. Boshkov LK. Transfusion-associated acute lung injury (TRALI): an evolving understanding of the role of anti-leukocyte antibodies. Vox Sang 2002;83(Suppl 1):299–303.10.1111/j.1423-0410.2002.tb05322.x12617157
  6. Barnard RD. Indiscriminate transfusion: a critique of case reports illustrating hypersensitivity reactions. N Y State J Med 1951;51:2399–402.
  7. Brittingham TE. Immunologic studies on leukocytes. Vox Sang 1957;2:242–8.10.1111/j.1423-0410.1957.tb03699.x13496693
  8. Popovsky MA, Abel MD, Moore SB. Transfusion-related acute lung injury associated with passive transfer of antileukocyte antibodies. Am Rev Respir Dis 1983;128:185–9.10.1164/arrd.1983.128.1.1856603182
  9. Popovsky MA, Moore SB. Diagnostic and pathogenetic considerations in transfusion-related acute lung injury. Transfusion 1985;25:573–7.10.1046/j.1537-2995.1985.25686071434.x4071603
  10. Toy P, Popovsky MA, Abraham E, et al. Transfusion-related acute lung injury: definition and review. Crit Care Med 2005;33:721–6.10.1097/01.CCM.0000159849.94750.51
  11. Kleinman S, Caulfield T, Chan P, et al. Toward an understanding of transfusion-related acute lung injury: statement of a consensus panel. Transfusion 2004;44:1774–89.10.1111/j.0041-1132.2004.04347.x15584994
  12. Phua J, Stewart TE, Ferguson ND. Acute respiratory distress syndrome 40 years later: time to revisit its definition. Crit Care Med 2008;36:2912–21.10.1097/CCM.0b013e31817d20bd18766113
  13. Ware LB, Matthay MA. The acute respiratory distress syndrome. N Engl J Med 2000;342:1334–49.10.1056/NEJM20000504342180610793167
  14. Palfi M, Berg S, Ernerudh J, Berlin G. A randomized controlled trial of transfusion-related acute lung injury: is plasma from multiparous blood donors dangerous? Transfusion 2001;41:317–22.10.1046/j.1537-2995.2001.41030317.x11274583
  15. Palfi M, Holthuis N. Does mild TRALI exist? Analysis of one year transfusion complications from south Sweden (abstract #M10.04). Vox Sang 2004;87 (Suppl 3):S4.
  16. Toy P, Hollis-Perry KM, Jun J, Nakagawa M. Recipients of blood from a donor with multiple HLA antibodies: a lookback study of transfusion-related acute lung injury. Transfusion 2004;44:1683–8.10.1111/j.0041-1132.2004.04193.x15584980
  17. Kopko PM, Marshall CS, MacKenzie MR, Holland PV, Popovsky MA. Transfusion-related acute lung injury: report of a clinical look-back investigation. JAMA 2002;287:1968–71.10.1001/jama.287.15.196811960539
  18. Dry SM, Bechard KM, Milford EL, Churchill WH, Benjamin RJ. The pathology of transfusion-related acute lung injury. Am J Clin Pathol 1999;112:216–21.10.1093/ajcp/112.2.21610439802
  19. Wyman TH, Bjornsen AJ, Elzi DJ, et al. A two-insult in vitro model of PMN-mediated pulmonary endothelial damage: requirements for adherence and chemokine release. Am J Physiol Cell Physiol 2002;283:C1592– 603.10.1152/ajpcell.00540.200112388071
  20. Condliffe AM, Kitchen E, Chilvers ER. Neutrophil priming: pathophysiological consequences and underlying mechanisms. Clin Sci (Lond) 1998;94:461–71.10.1042/cs09404619682667
  21. Silliman CC, Kelher M. The role of endothelial activation in the pathogenesis of transfusion-related acute lung injury. Transfusion 2005;45(Suppl):109S– 16S.10.1111/j.1537-2995.2005.00531.x16086797
  22. Fung YL, Silliman CC. The role of neutrophils in the pathogenesis of transfusion-related acute lung injury. Transfus Med Rev 2009;23:266–83.10.1016/j.tmrv.2009.06.001293722119765516
  23. Silliman CC, Curtis BR, Kopko PM, et al. Donor antibodies to HNA-3a implicated in TRALI reactions prime neutrophils and cause neutrophil-mediated damage to human pulmonary microvascular endothelial cells in a two-event in vitro model. Blood 2007;109:1752–5.10.1182/blood-2006-05-025106179405517038531
  24. Kelher MR, Masuno T, Moore EE, et al. Plasma from stored packed red blood cells and MHC class 1 antibodies causes acute lung injury in a 2-event in vivo rat model. Blood 2009;113:2079–87.10.1182/blood-2008-09-177857265101819131548
  25. Seeger W, Schneider U, Kreusler B, et al. Reproduction of transfusion-related acute lung injury in an ex vivo lung model. Blood 1990;76:1438–44.10.1182/blood.V76.7.1438.1438
  26. Sachs UJH, Hattar K, Weissmann N, et al. Antibody-induced neutrophil activation as a trigger for transfusion-related acute lung injury in an ex vivo rat lung model. Blood 2006;107:1217–19.10.1182/blood-2005-04-174416210340
  27. Lögdberg LE, Vikulina T, Zimring JC, Hillyer CD. Animal models of transfusion-related acute lung injury. Transfus Med Rev 2009;23:13–24.10.1016/j.tmrv.2008.09.00219056031
  28. Win N, Ranasinghe E, Lucas G. Transfusion-related acute lung injury: a 5-year look-back study. Transfus Med 2002;12:387–9.10.1046/j.1365-3148.2002.00401_1.x12473157
  29. Nicolle AL, Chapman CE, Carter V, Wallis JP. Transfusion-related acute lung injury caused by two donors with anti-human leucocyte antigen class II antibodies: a look-back investigation. Transfus Med 2004;14:225–30.10.1111/j.0958-7578.2004.00504.x15180814
  30. Davoren A, Curtis BR, Shulman IA, et al. TRALI due to granulocyte-agglutinating human neutrophil antigen3a (5b) alloantibodies in donor plasma: a report of 2 fatalities. Transfusion 2003;43:641–5.10.1046/j.1537-2995.2003.00374.x12702187
  31. Muniz M, Sheldon S, Schuller RM, et al. Patient-specific transfusion-related acute lung injury. Vox Sang 2008;94:70–3.
  32. Fadeyi EA, De Los Angeles Muniz M, Wayne AS, Klein HG, Leitman SF, Stroncek DF. The transfusion of neutrophil-specific antibodies causes leukopenia and a broad spectrum of pulmonary reactions. Transfusion 2007;47:545–50.10.1111/j.1537-2995.2006.01148.x17319838
  33. Kopko PM, Paglieroni TG, Popovsky MA, Muto KN, MacKenzie MR, Holland PV. TRALI: correlation of antigen-antibody and monocyte activation in donor-recipient pairs. Transfusion 2003;43:177–84.10.1046/j.1537-2995.2003.00307.x12559013
  34. Gosselin EJ, Wardwell K, Rigby WF, Guyre PM. Induction of MHC class II on human polymorphonuclear neutrophils by granulocyte/macrophage colony-stimulating factor, IFN-gamma, and IL-3. J Immunol 1993;151:1482–90.
  35. Kao GS, Wood IG, Dorfman DM, Milford EL, Benjamin RJ. Investigations into the role of anti-HLA class II antibodies in TRALI. Transfusion 2003;43:185–91.10.1046/j.1537-2995.2003.00285.x12559014
  36. Bux J, Sachs UJH. Pathophysiology of TRALI. In: Kleinman SH, Popovsky MA, eds. TRALI: mechanisms, management and prevention. Bethesda, MD: AABB Press, 2008:43–69.
  37. Nishimura M, Hashimoto S, Takanashi M, Okazaki H, Satake M, Nakajima K. Role of anti-human leucocyte antigen class II alloantibody and monocytes in development of transfusion-related acute lung injury. Transfus Med 2007;17:129–34.10.1111/j.1365-3148.2006.00721.x17430469
  38. Looney MR, Su X, Van Ziffle JA, Lowell CA, Matthay MA. Neutrophils and their Fcγ receptors are essential in a mouse model of transfusion-related acute lung injury. J Clin Invest 2006;116:1615–23.10.1172/JCI27238146294516710475
  39. Dykes A, Smallwood D, Kotsimbos T, Street A. Transfusion-related acute lung injury (TRALI) in a patient with a single lung transplant. Br J Haematol 2000;109:674–6.10.1046/j.1365-2141.2000.01999.x10886228
  40. Silliman CC, Paterson AJ, Dickey WO, et al. The association of biologically active lipids with the development of transfusion-related acute lung injury: a retrospective study. Transfusion 1997;37:719–26.10.1046/j.1537-2995.1997.37797369448.x9225936
  41. Vercellotti GM, Yin HQ, Gustafson KS, Nelson RD, Jacob HS. Platelet-activating factor primes neutrophil responses to agonists: role in promoting neutrophil-mediated endothelial damage. Blood 1988;71:1100–7.10.1182/blood.V71.4.1100.1100
  42. Berkow RL, Wang D, Larrick JW, Dodson RW, Howard TH. Enhancement of neutrophil superoxide production by preincubation with recombinant human tumor necrosis factor. J Immunol 1987;139:3783–91.
  43. Daniels RH, Finnen MJ, Hill ME, Lackie JM. Recombinant human monocyte IL-8 primes NADPH-oxidase and phospholipase A2 activation in human neutrophils. Immunology 1992;75:157–63.
  44. Guthrie LA, McPhail LC, Henson PM, Johnston RB Jr. Priming of neutrophils for enhanced release of oxygen metabolites by bacterial lipopolysaccharide. Evidence for increased activity of the superoxide-producing enzyme. J Exp Med 1984;160:1656–71.10.1084/jem.160.6.165621875296096475
  45. Silliman CC, Bjornsen AJ, Wyman TH, et al. Plasma and lipids from stored platelets cause acute lung injury in an animal model. Transfusion 2003;43:633–40.10.1046/j.1537-2995.2003.00385.x12702186
  46. Silliman CC, Voelkel NF, Allard JD, et al. Plasma and lipids from stored packed red blood cells cause acute lung injury in an animal model. J Clin Invest 1998;101:1458–67.10.1172/JCI18415087249525989
  47. Silliman CC, Thurman GW, Ambruso DR. Stored blood components contain agents that prime the neutrophil NADPH oxidase through the platelet-activating-factor receptor. Vox Sang 1992;63:133–6.
  48. Silliman CC, Johnson CA, Clay KL, Thurman GW, Ambruso DR. Compounds biologically similar to platelet activating factor are present in stored blood components. Lipids 1993;28:415–18.10.1007/BF025359398316049
  49. Silliman CC, Clay KL, Thurman GW, Johnson CA, Ambruso DR. Partial characterization of lipids that develop during the routine storage of blood and prime the neutrophil NADPH oxidase. J Lab Clin Med 1994; 124:684–94.
  50. Khan SY, Kelher MR, Heal JM, et al. Soluble CD40 ligand accumulates in stored blood components, primes neutrophils through CD40, and is a potential cofactor in the development of transfusion-related acute lung injury. Blood 2006;108:2455–62.10.1182/blood-2006-04-017251189556416772606
  51. Silliman CC, Dickey WO, Paterson AJ, et al. Analysis of the priming activity of lipids generated during routine storage of platelet concentrates. Transfusion 1996;36:133–9.10.1046/j.1537-2995.1996.36296181925.x8614963
  52. Eder AF, Herron R, Strupp A, et al. Transfusion-related acute lung injury surveillance (2003–2005) and the potential impact of the selective use of plasma from male donors in the American Red Cross. Transfusion 2007;47:599–607.10.1111/j.1537-2995.2007.01102.x17381617
  53. Looney MR, Nguyen JX, Hu Y, Van Ziffle JA, Lowell CA, Matthay MA. Platelet depletion and aspirin treatment protect mice in a two-event model of transfusion-related acute lung injury. J Clin Invest 2009;119:3450–61.10.1172/JCI38432276918119809160
  54. Engelfriet CP, Reesink HW, Brand A, et al. Transfusion-related acute lung injury (TRALI). Vox Sang 2001;81:269–83.10.1046/j.0042-9007.2001.00115_1.x11904006
  55. Swanson K, Dwyre DM, Krochmal J, Raife TJ. Transfusion-related acute lung injury (TRALI): current clinical and pathophysiologic considerations. Lung 2006;184:177–85.10.1007/s00408-005-2578-816902843
  56. Bux J, Sachs UJH. The pathogenesis of transfusion-related acute lung injury (TRALI). Br J Haematol 2007;136:788–99.10.1111/j.1365-2141.2007.06492.x17341264
  57. Chapman CE, Stainsby D, Jones H, et al. Ten years of hemovigilance reports of transfusion-related acute lung injury in the United Kingdom and the impact of preferential use of male donor plasma. Transfusion 2009;49:440–52.10.1111/j.1537-2995.2008.01948.x18980623
  58. Densmore TL, Goodnough LT, Ali S, Dynis M, Chaplin H. Prevalence of HLA sensitization in female apheresis donors. Transfusion 1999;39:103–6.10.1046/j.1537-2995.1999.39199116901.x9920173
  59. Triulzi DJ, Kleinman S, Kakaiya RM, et al. The effect of previous pregnancy and transfusion on HLA alloimmunization in blood donors: implications for a transfusion-related acute lung injury risk reduction strategy. Transfusion 2009;49:1825–35.10.1111/j.1537-2995.2009.02206.x284100119453983
  60. Hume HA. TRALI: moving toward prevention. Transfusion 2009;49:402–5.10.1111/j.1537-2995.2008.02090.x19243538
  61. Strong DM, Lipton KS. Transfusion-related acute lung injury. American Association of Blood Banks Bulletin#06-07, Nov 3, 2006.
  62. Eder AF, Herron RM Jr, Strupp A, et al. Effective reduction of transfusion-related acute lung injury risk with male-predominant plasma strategy in the American Red Cross (2006–2008). Transfusion 2010 Apr 30 [Epub ahead of print].10.1111/j.1537-2995.2010.02652.x20456698
  63. Chapman CE, Williamson LM. UK hemovigilance and the preferential use of male plasma. In: Kleinman SH, Popovsky MA, eds. TRALI: mechanisms, management and prevention. Bethesda, MD: AABB Press, 2008:143–60.
  64. Sinnott P, Bodger S, Gupta A, et al. Presence of HLA antibodies in single-donor-derived fresh frozen plasma compared with pooled, solvent detergent-treated plasma (Octaplas). Eur J Immunogenet. 2004; 31:271–4.10.1111/j.1365-2370.2004.00481.x15548265
  65. Sachs UJ, Kauschat D, Bein G. White blood cell-reactive antibodies are undetectable in solvent/ detergent plasma. Transfusion. 2005;45:1628–31.10.1111/j.1537-2995.2005.00587.x16181214
  66. Triulzi DJ. Transfusion-related acute lung injury: current concepts for the clinician. Anesth Analg 2009; 108:770–6.10.1213/ane.0b013e31819029b219224781
  67. Mair DC, Hirschler N, Eastlund T. Blood donor and component management strategies to prevent transfusion-related acute lung injury (TRALI). Crit Care Med 2006;34(Suppl):S137–43.10.1097/01.CCM.0000214291.93884.BB16617258
  68. Greinacher A, Wesche J, Hammer E, et al. Characterization of the human neutrophil alloantigen3a. Nat Med 2010;16:45–8.10.1038/nm.207020037594
  69. Curtis BR, Cox NJ, Sullivan MJ, et al. The neutrophil alloantigen HNA-3a (5b) is located on choline transporter-like protein 2 and appears to be encoded by an R>Q154 amino acid substitution. Blood 2010 115:2073–6.10.1182/blood-2009-11-248336283733220040764
  70. Silliman CC, Ambruso DR, Boshkov LK. Transfusion-related acute lung injury. Blood 2005;105:2266–73.10.1182/blood-2004-07-292915572582
  71. Goldman M, Webert KE, Arnold DM, Freedman J, Hannon J, Blajchman MA; TRALI Consensus Panel. Proceedings of a consensus conference: towards an understanding of TRALI. Transfus Med Rev 2005;19: 2–31.10.1016/j.tmrv.2004.10.00115830325
DOI: https://doi.org/10.21307/immunohematology-2019-215 | Journal eISSN: 1930-3955 | Journal ISSN: 0894-203X
Language: English
Page range: 61 - 73
Published on: Mar 14, 2020
Published by: American National Red Cross
In partnership with: Paradigm Publishing Services
Publication frequency: 4 times per year

© 2020 D.C. Mair, T. Eastlund, published by American National Red Cross
This work is licensed under the Creative Commons License.